All In Biotech

NDA 018565 · Hikma

Duramorph Pf

Morphine Sulfate · Injection

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Sep 18, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,053

400 Phase 3, 129 recruiting

FAERS reports

67,829

52,335 serious, 12,175 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF INFUMORPH Risks with Neuraxial Administration Single-dose neuraxial administration may result in acute or delayed respiratory depression up to 24 hours. Because of the risk of severe adverse reactions when INFUMORPH is administered by the epidural or intrathecal route of administration, patients must be observed in a fully equipped and staffed environment for at least 24 hours after the initial dose [ see Warnings and Precautions ( 5.1 ) ]. Addiction, Abuse, and Misuse Because the use of INFUMORPH exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [ see Warnings and Precautions ( 5.2 ) ]. Life-Threatening Respiratory...

What it is approved for

From the label in effect Dec 31, 2025.

INFUMORPH is for use in continuous microinfusion devices and indicated only for intrathecal or epidural infusion in the management of intractable chronic pain severe enough to require an opioid analgesic and for which less invasive means of controlling pain are inadequate. Limitations of Use Not for single-dose intravenous, intramuscular, or subcutaneous administration due to the risk of overdose. Not for single-dose neuraxial injection because INFUMORPH is too concentrated for accurate delivery of the smaller doses used in this setting. INFUMORPH is an opioid agonist, for use in continuous microinfusion devices and indicated only for intrathecal or epidural infusion in the management of intractable chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) Limitations of Use: Not for single-dose intravenous, intramuscular, or subcutaneous administration due to the risk of overdose. Not for single-dose neuraxial injection because INFUMORPH is too concentrated for accurate delivery of the smaller doses used in this setting. ( 1)

Mechanism: Morphine is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 18, 1984 Original approval · Type 3 - New Dosage Form · priority review
4 products under this application
  • DURAMORPH PF · MORPHINE SULFATE 0.5MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • INFUMORPH · MORPHINE SULFATE 25MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DURAMORPH PF · MORPHINE SULFATE 1MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • INFUMORPH · MORPHINE SULFATE 10MG/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Morphine" as an intervention, any sponsor and status, largest first.

All 2,053 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug dependence10,517
  • drug hypersensitivity10,163
  • pain9,255
  • overdose7,799
  • emotional distress5,180
  • nausea4,701
  • dependence4,682
  • drug ineffective4,503
  • death4,265
  • fatigue3,376
  • drug withdrawal syndrome3,368
  • vomiting3,316

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,243
20051,049
2006952
2007530
2008649
2009698
2010892
20111,190
20121,842
20131,474
20141,863
20152,362
20162,934
20172,716
20185,586
20194,365
20203,846
20217,875
20228,457
20238,188
20243,561
20253,353
20262,201

Recalls

1 FDA enforcement reports for this application.

  • Mar 12, 2024 · Class II · Ongoing

    The filter included in the carton has an expiration date that has expired prior to the expiration date of the actual product lot.

Shortages

FDA's drug shortage list.

  • Current · updated Oct 14, 2026

    Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10). Additional lots are scheduled to be manufactured. Product will be made available as it is released.

  • Current · updated Oct 14, 2026

    Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01). Demand increase for the drug

  • Current · updated Oct 14, 2026

    Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01). Additional lots are scheduled to be manufactured. Product will be made available as it is released.

  • Current · updated Oct 14, 2026

    Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10). Additional lots are scheduled to be manufactured. Product will be made available as it is released.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8,877 on PubMed

Sponsor: Hikma · Also marketed as Infumorph

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.